44 results
8-K
EX-99.1
BTAX
Biostax Corp.
9 Jul 13
Other Events
12:00am
to the meeting. If the materials presented in the information package are inadequate to prepare for the meeting or if we do not
receive the package
8-K
BTAX
Biostax Corp.
25 Sep 13
Other Events
12:00am
, TNI BioTech, LTD submitted a pre-submission package to the EMA regarding Crohn’s Disease. The EMA granted the Company a meeting scheduled for Friday
8-K
EX-10.1
BTAX
Biostax Corp.
20 Mar 20
Immune Therapeutics, Inc. to Collaborate with Cytocom, Inc. to Develop Therapies for COVID-19
11:43am
will be responsible Type C Meeting with the FDA on behalf of CYTO.
2.5 IMUN will be responsible for providing final briefing package and protocols for COVID
8-K
BTAX
Biostax Corp.
25 Sep 19
Entry into a Material Definitive Agreement
5:05pm
entitled to receive employee benefits afforded under the Company’s standard written benefits package to regular full-time employees of the Company
8-K
EX-10.1
BTAX
Biostax Corp.
27 Jul 20
Departure of Directors or Certain Officers
3:07pm
. If notice of termination of Executive by Immune is affected after March 30, 2021, Executive shall qualify for a six-month severance package equal
10-12G/A
EX-10.12
kvhgneblbdty
23 Aug 13
Registration of securities (amended)
12:00am
S-1
24n2e
14 Oct 16
IPO registration
12:00am
DRS/A
gt1el 83nia3
14 Oct 16
Draft registration statement (amended)
12:00am
8-K
EX-1.1
g3lu0x ed3hhy
25 Jun 14
Entry into a Material Definitive Agreement
12:00am
10-K
EX-10.18
cny6j6
31 Mar 14
Annual report
12:00am